Compare Recursion Pharmaceuticals Inc (RXRX) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B), while Direxion Daily FTSE China Bull 3x Shares trades at $24.57 (market cap $560.32M). The key difference: Recursion Pharmaceuticals Inc is far larger — about 3.8× Direxion Daily FTSE China Bull 3x Shares's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| RXRX | YINN | |
|---|---|---|
Market Cap | $2.14B | $560.32M |
Volume | 30,789,535 | 1,009,521 |
Sector | Health | Leveraged / Inverse |
52-Week High | $6.79 | $52.69 |
52-Week Low | $2.84 | $21.45 |
Typical Hold Time | 22 Days | 25 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
YINN is trading at $23.56, down 2.97% with bearish technical indicators showing 18 sell signals versus 1 buy. The stock faces resistance at $24 with support at $23. Recent corporate actions include a $0.56 dividend scheduled for September 2026. Technical analysis indicates strong bearish momentum with moving averages unanimously negative.
The outlook remains challenging with bearish technical positioning and limited fundamental data availability. Key risks include market volatility and sector-specific headwinds. Investment opportunities may emerge if the stock stabilizes above support levels, but current momentum suggests continued downward pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
